(Q40758666)

English

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab (English)

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

0 references

0 references

Mariaelena Capone

6

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

10

object named as

Antje Sucker

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Dirk Schadendorf

11

object named as

Dirk Schadendorf

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Paolo Antonio Ascierto

14

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Jedd D. Wolchok

15

object named as

Jedd D Wolchok

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

16

object named as

Graham Pawelec

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Kilian Wistuba-Hamprecht

object named as

Kilian Wistuba-Hamprecht

2

1 reference

ORCID Public Data File 2021

author name string

Alexander Martens

1

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Jianda Yuan

3

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Michael A Postow

4

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Phillip Wong

5

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Gabriele Madonna

7

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Amir Khammari

8

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Bastian Schilling

9

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Peter Martus

12

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Brigitte Dreno

13

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Claus Garbe

17

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Benjamin Weide

18

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

language of work or name

0 references

publication date

11 May 2016

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

22

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

19

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

4848-4858

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Coordinated regulation of myeloid cells by tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

24 September 2017

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

25 September 2017

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

17 June 2018

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

17 June 2018

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

17 June 2018

Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

17 June 2018

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

19 August 2018

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

19 August 2018

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

19 August 2018

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

19 August 2018

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

19 August 2018

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

19 August 2018

Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

19 August 2018

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

2 December 2018

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5544386

2 December 2018

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27169993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of intratumoral natural killer cells in gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27169993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/27169993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-16-0249

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

release_6ynytpkvvvawfnb2blqft6skhu

1 reference

https://api.fatcat.wiki/v0/release/6ynytpkvvvawfnb2blqft6skhu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40758666&oldid=1906731485"